Major Depressive Disorder Clinical Trials in Philadelphia, Pennsylvania

10 studies are recruiting for major depressive disorder in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Decoding and Modulating Affective Brain States

   The research study is being conducted to study brain patterns of negative emotion and develop personalized brain stimulation protocols to disrupt these patterns with transcranial magnetic stimulation (TMS). First, the investigators will use functional Magnetic Resonance Imaging (fMRI) data to gener…

   Stage

   Not phased

   Ages

   18 to 65

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   University of Pennsylvania

   See if you can join NCT05437705 on ClinicalTrials.gov

2. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

   This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania

   Locations

   69 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT05850689 on ClinicalTrials.gov

3. NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Philadelphia, Pennsylvania

   Locations

   35 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06963021 on ClinicalTrials.gov

4. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

   A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   Adams Clinical Philadelphia, Philadelphia, Pennsylvania

   Locations

   30 in total

   Run by

   Definium Therapeutics US, Inc.

   See if you can join NCT07592689 on ClinicalTrials.gov

5. A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

   X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   Adams Clinical - Philadelphia, Philadelphia, Pennsylvania

   Locations

   51 in total

   Run by

   Xenon Pharmaceuticals Inc.

   See if you can join NCT06775379 on ClinicalTrials.gov

6. A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

   The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   Adams Clinical, Philadelphia, Pennsylvania

   Locations

   32 in total

   Run by

   Syndeio Biosciences, Inc

   See if you can join NCT07115329 on ClinicalTrials.gov

7. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Philadelphia, Pennsylvania

   Locations

   106 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06966401 on ClinicalTrials.gov

8. A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Philadelphia, Pennsylvania

   Locations

   60 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07196501 on ClinicalTrials.gov

9. Triage Survey for Psychiatry Research Eligibility

   TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Adams Clinical, Philadelphia, Philadelphia, Pennsylvania

   Locations

   6 in total

   Run by

   Adams Clinical

   See if you can join NCT05800925 on ClinicalTrials.gov

10. Taking Action for College Students

    The goal of this research is to investigate whether a peer-delivered illness self-management program called Taking Action can help college students with serious mental illnesses. Participants will be randomly assigned to either the experimental condition (Taking Action) or the control condition (in…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Temple University, Philadelphia, Pennsylvania

    Run by

    Temple University

    See if you can join NCT06700902 on ClinicalTrials.gov